The Huanglongbing disease is spread by the Asian Citrus Psyllid shown above. Image courtesy Georgia Dept. of Agriculture.Pasadena Now has learned that 77 trees in nearby communities are infected with a bacteria that is decimating citrus fruit production across the country. At least 76 trees in nearby San Gabriel are infected with Huanglongbing (HLB). Another tree carrying the bacteria was found in Alhambra as of Jan. 17.Both communities are part of the five-square mile radius citrus fruit quarantine that includes Pasadena. The quarantine prohibits the removal of homegrown, non-commercial citrus fruit from the area. Fruit from markets and certified farmer’s markets is exempt.HLB has not been discovered in Pasadena.HLB starves trees after it enters their circulatory system. It is not known if the infected trees have been removed. It is not harmful to humans or animals.In 2017, infected trees were also found in the area.The California Department Food and Agriculture declared the quarantine which bars the movement of home-grown non commercial fruit from the area.Fruit from stores is not subject to the quarantine.According to one person working at the CDFA, the CDFA does not patrol quarantine areas.The bacteria can be transferred from one tree to another by the Asian Citrus Psyllid, a sap sucking pest that can carry the bacteria from one tree to another as it feeds. The bacteria can also be transferred by grafting cuttings from one tree to another.HLB was first detected in 2005. Since that time, orange production has fallen by more than 75 percent, and grapefruit production is down 85 percent. Backyard citrus has virtually disappeared in some areas, according to reports.According to Victoria Hornbaker, director of the citrus pest and disease prevention division at the California Department Food and Agriculture (CDFA), trees infected by the bacteria experience stunted growth, bear off season flowers, and produce irregularly shaped fruit with a thick, pale peel that remains green at the bottom and tastes very bitter.HLB has also been found in Los Angeles, San Bernardino and Riverside counties.Officials will hang traps and take samples of local trees for testing.The disease has infected about 75 percent of citrus trees in Florida and placed the entire state in a quarentine zone, resulting in more than $4 billion in lost citrus. More than 26 million citrus trees have been lost in Brazil.In Florida crop owners have not been forced to remove trees, because they are primarily producing fruit from the trees. In California, trees would have to be removed according to Hornbaker, director of the citrus pest and disease prevention division.“We have commercial citrus production, Riverside and San Bernardino. If HLB were to get into commercial grove, then that grove owner would be removing trees. It would be potentially impacting their production. Our fruit that we produce in California is the fruit that you’re going to find on your table, so that will be an impact for us.” More Cool Stuff 17 recommendedShareShareTweetSharePin it Make a comment Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Donald CommunityPCC- COMMUNITYVirtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyPasadena Public WorksPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS First Heatwave Expected Next Week HerbeautyWant To Seriously Cut On Sugar? You Need To Know A Few TricksHerbeautyHerbeautyHerbeauty6 Lies You Should Stop Telling Yourself Right NowHerbeautyHerbeautyHerbeautyIt Works Great If Weight Loss Is What You’re Looking For!HerbeautyHerbeautyHerbeautyThese Are 15 Great Style Tips From Asian WomenHerbeautyHerbeautyHerbeautyEase Up! Snake Massages Are Real And Do Wonders!HerbeautyHerbeautyHerbeautyFinding The Right Type Of Workout For You According AstrologyHerbeautyHerbeauty Top of the News Business News Community News Community News Community News Citrus Disease Creeps Close to Pasadena, Officials Find Infected Alhambra, San Gabriel Trees Dozens of trees could be infected in the area By ANDRÉ COLEMAN, Managing Editor Published on Friday, January 24, 2020 | 5:14 am Name (required) Mail (required) (not be published) Website Subscribe Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Your email address will not be published. Required fields are marked * Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadena
Are Europe’s large pharma companies thematically too diversified? Are there opportunities to invest in smaller companies emulating the US market? The fact 85-90% of one of Europe’s largest healthcare funds is invested in the US suggests Europe faces some significant long-term challenges if it wishes to retain its pre-eminence in healthcare. The manager prefers small and mid-sized companies as new investment ideas that have a clear world-class expertise and a focus on specific areas, which he holds for upwards of five years. He sees Europe’s large pharma companies as solid, good companies but argues that they are thematically too diversified, or even run as healthcare conglomerates.Europe does not see the plethora of small and mid-sized spinoffs and start-ups that are seen in the US, but the US is not its only rival. China and India have well-established pharmaceutical industries, and, with an abundance of brainpower, they are well positioned to produce streams of cutting-edge healthcare companies.Europe’s healthcare industry can be divided into three segments, with a handful of giants – the UK’s GSK, the British-Swedish AstraZeneca, the Swiss Novartis and Roche, France’s Sanofi, Danish diabetes specialist Novo Nordisk and possibly the German company Fresenius. Beneath the pharma giants is a set of mid-sized companies that, for historical reasons, are owned by foundations or families, such as the Danish company Lundbeck, the French company Ipsen, the Spanish companies Rovi and Almirall and the Italian company Recordati. Beneath this are hundreds of emerging biotech companies – some very tiny and others of reasonable size. But the biotech industry is very much weighted towards the US, versus Europe. There are many reasons for this, including the availability of risk capital.Pharma is still perceived as being a safer-haven, low-volatility sector. Over the long term, it would generate lower returns than biotech but outperform the broader market. Biotech is still perceived as an innovation industry that is more volatile. But the US companies such as Celgene are producing double-digit revenue growth rates with very high sustainable profit margins. For Europe as a whole though, the issue may not be purely one of generating short-term investment returns. If the jewel in its crown is not to be tarnished over the long term, Europe’s pharmaceutical sector must find a way to emulate the success of the biotech companies in the US.Joseph Mariathasan is a contributing editor at IPE Europe’s pharmaceutical sector must find a way to emulate US biotech, Joseph Mariathasan writesThe European pharmaceutical industry is arguably the jewel in the crown of Europe’s industrial base, and GlaxoSmithKline (GSK) is one of the UK’s giants. It showed its strength last week when it filed its shingles vaccine Shingrix for US regulatory approval. Analysts estimate that the drug, one of GSK’s most promising experimental products, could generate revenues of $1bn (€909m) a year.But Europe faces some significant long-term challenges if it wishes to retain its pre-eminence in healthcare. GSK may be an example of what could be the problem – it needs to revitalise a drug portfolio characterised by reliance on a few blockbusters now seeing falling sales, such as its inhaled lung treatment Advair. The US patent on this expired in 2010, so it is only a matter of time before generic versions destroy its revenues.PwC estimates that almost half of all corporate research and development in the in UK in 2016 has been accounted for by the healthcare and pharmaceutical industry. Clearly, the sector has immense strengths, but the problem is that virtually all of that figure is accounted for by just two companies – GSK and AstraZeneca. Europe has not seen the plethora of small and mid-sized spinoffs and start-ups that characterise the US healthcare market.
“The sky is the limit for her, it really is. I am saying now she will probably make the WTA Finals and a Grand Slam, maybe. “With a good draw, some luck and with what she has shown last week, you don’t want to put too much expectation on her, but she was not expected to win Indian Wells and look what happened.”A Grand Slam might be next year, but you just don’t know. She has incredible determination and drive. She will stay grounded, there will be no issue with that and she can achieve so much.” Bianca Andreescu visualized unlikely Indian Wells win: ‘A Cinderella story’ Bianca Andreescu’s former coach Andre Labelle says the teenage sensation can win a Grand Slam this year after her astonishing Indian Wells Open triumph.Andreescu made history on Sunday by beating three-time major champion Angelique Kerber 6-4, 3-6, 6-4 to become the first wild card to win the prestigious title in California. The 18-year-old Canadian started the year outside the top 150, but rose to 24th on Monday after seeing off the likes of Garbine Muguruza and Elina Svitolina before stunning Kerber.From a wild card to the Indian Wells champion – Bianca Andreescu just made history. Congratulations, @Bandreescu_! #BiancaRising 🎾🇨🇦 https://t.co/0IBTOfcZQH— Justin Trudeau (@JustinTrudeau) March 18, 2019Labelle, who nurtured Andreescu’s talent for almost four years at Tennis Canada, believes the rising star’s first WTA Tour triumph will most definitely not be a flash in the pan. Related News “Before Indian Wells, the goal for Bianca was top 50 at the end of the year,” the Tennis Canada national coach told Omnisport. “So now obviously that will be changed. There are three Grand Slams and more Premier events to come, so many, many more points to be won